> *+,./ l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1Courier New1Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)**_($* #,##0_);_($* (#,##0);_($* ""_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* ""_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* ""??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* ""??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)60%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0) + ) , * Ј ~~ ؈ ~~#؈ ~~ ؈ ~~8#܈ ~~9#܈ ~~4#܈ ~~3#܈ ~~7#܈ ~~83ffff̙̙3f3fff3f3f33333f33&cJAZZ PHARMACEUTICALS PUBLIC LIM&Waterloo Road Dublin 4 Ireland &
SIGNATURES&>CONDENSED CONSOLIDATED BALANCE &^CONDENSED CONSOLIDATED STATEMEN&dCONDENSED CONSOLIDATED STAT (1)&CONDENSED CONSOLIDATED STAT (2)&CONDENSED CONSOLIDATED STAT (3)&!CONDENSED CONSOLIDATED STAT (4)&LJAdoption of New Accounting StanF]Asset Acquisition&zl3 Cash and AvailableforSale Sec&3 Cash and AvailableforSale (1)d4 Fair Value Measurement&5 Derivative Instruments and He&5 Derivative Instruments an (1)&5 Derivative Instruments an (2)&5 Derivative Instruments an (3)&a5 Derivative Instruments an (4)&5 Derivative Instruments an (5),
6 Inventories&$7 Goodwill and Intangible Asset&07 Goodwill and Intangible A (1)&J7 Goodwill and Intangible A (2)$.X8 Certain Balance Sheet Items$i8 Certain Balance Sheet I (1)
}9 Debt
Maturities 10 LeasesR
10 Leases (1)*
10 Leases (2)k
10 Leases (3)
10 Leases (4)&wAccumulated Other Comprehensive&$13 Net Income per Ordinary Shar& 13 Net Income per Ordinary (1)14 Revenues ,14 Revenues (1)<14 Revenues (2)&JContract Liabilities Deferred R!W15 ShareBased CompensationWj
Share Options~Restricted Stock UnitsSleepNeuroscienceeHematologyOncologyxResults of OperationsRevenues&Research and Development Expens&To continue to grow our busines&Issuer Purchases of Equity SecuU!provided however&.A general release does not exte&:A general release does not (1)&FA general release does not (2)
l h
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }%}
Jazz Pharmaceuticals plc10Q
11/05/20193+JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
Ireland
981032470'(State or other jurisdiction of(I.R.S. Employer&incorporation or organization)Identification No.)
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(Tsg[OC+rfZ2=PF0*8X>
@
l Q&
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }U}$}$ }}$
Jazz Pharmaceuticals plc10Q
11/05/20191)Waterloo Road, Dublin 4, Ireland D04 E5W7
Large accelerated filer
?
Accelerated filer
?Nonaccelerated filer ?!Smaller reporting company ?
Emerging growth company ?$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,ui]QE gk_S+=PF0*8X>
@
l 96t=
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland !CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }y
}:}
9
Jazz Pharmaceuticals plc10Q
11/05/2019
SIGNATURES
Page&PART I  FINANCIAL INFORMATION
Item 1.
Financial Statements~
%Condensed Consolidated Balance Sheets~
% September 30, 2019 and December 31,~
,$Condensed Consolidated Statements of~
6.Income  Three and Nine Months Ended September30, 2019 and 2018,$Condensed Consolidated Statements of~
%Comprehensive Income  Three and Nine0(Months Ended September 30, 2019 and 2018,$Condensed Consolidated Statements of~
4,Shareholders? Equity  Three and Nine Months)!Ended September 30, 2019 and 2018,$Condensed Consolidated Statements of~
"0(Cash Flows  Nine Months Ended September30, 2019 and 20181)Notes to Condensed Consolidated Financial~
&
StatementsD4lpd@}2K"[J
!"#$%&'()*+,./012345678 Item 2., $Management?s Discussion and Analysis~
n!8!0of Financial Condition and Results of Operations"""#Item 3.0#(Quantitative and Qualitative Disclosures~
#$$About Market Risk%%%&Item 4.&Controls and Procedures~
&''#(PART II  OTHER INFORMATION()))*Item 1A.*Risk Factors~
*+++,Item 2./,'Unregistered Sales of Equity Securities~
,Band Use of Proceeds.../Item 5./Other Information~
/F0001Item 6.1Exhibits~
1F2223
SIGNATURES~
3N45$6____________________________17)Created by Morningstar Document Research.08(http://documentresearch.morningstar.com/6gC]E<V2=PF0*8X>
@288776633((
l :P[
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }2}$ }$}$ }$
:
Jazz Pharmaceuticals plc10Q
11/05/2019%CONDENSED CONSOLIDATED BALANCE SHEETS
September 30,
December 31,~
~
ASSETS
Current assets:
!Cash and cash equivalents~
0~
Investments~
~
n.&Accounts receivable, net of allowances~
^L~
zInventories~
W~
r;Prepaid expenses~
~
Other current assets~
~
Total current assets~
\~
VQK*"Property, plant and equipment, net~
~
:Operating lease assets~
ڨ Intangible assets, net~
D~
Goodwill~
W7~
:8 Deferred tax assets, net~
":~
^ Deferred financing costs~
~
֕ Other noncurrent assets~
ʳ~
"Total assets~
dQ~
=,$LIABILITIES AND SHAREHOLDERS? EQUITYCurrent liabilities:Accounts payable~
bG~
jzD'lymaUIl6;rV%m M !"#$%&'()*+,./0123456789 Accrued liabilities~
R ~
* )!!Current portion of longterm debt~
! !!~
! !"Income taxes payable~
"""~
""#Deferred revenue~
#I##~
#T#!$Total current liabilities~
$$$~
$>$%%Deferred revenue, noncurrent~
%f^%%~
%%,&$Longterm debt, less current portion~
&v_&&~
&Ff_&1')Operating lease liabilities, less current~
'j] '' ''(portion%)Deferred tax liabilities, net~
)D))~
))%*Other noncurrent liabilities~
*B**~
*[
*/+'Commitments and contingencies (Note 11)++++,Shareholders? equity:,,,Ordinary shares~
~
'.Nonvoting euro deferred shares~
...~
.."/Capital redemption reserve~
/b//~
/b/"0Additional paidin capital~
0ֆ00~
0z0,1$Accumulated other comprehensive loss1 ( 259,442 1)11 ( 197,791 1)2Retained earnings~
2zdC22~
2jU32"3Total shareholders? equity~
3m33~
3L324*Total liabilities and shareholders? equity~
4dQ44~
4=456$7____________________________18)Created by Morningstar Document Research.09(http://documentresearch.morningstar.com/8
4x:J~9s
'd=PF0*8X>
@ZK99887744443333222211110000////....****))))''''&&&&%%%%$$$$####""""!!!!
l 0qw
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }6}$ }$}$ }$}
$ }$}$ }$
0
Jazz Pharmaceuticals plc10Q
11/05/20193+CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
Revenues:
Product sales, net~
} ~
d~
(_~
nU'Royalties and contract revenues~
T~
BA~
JG~
Total revenues~
~
~
o`~
UVOperating expenses:
5Cost of product sales (excluding amortization~
~
:~
~
of intangible assets)+#Selling, general and administrative~
J
~
~
~
Research and development~
~
b~
Y~
_
%Intangible asset amortization~
>~
6~
2~
.u Impairment charges   ~
B4,Acquired inprocess research and development~
( ~
^
 Total operating expenses~
ޱ~
R ~
rC~
<Income from operations~
~
~
f~
^;Interest expense, net( 17,861 )( 18,920 ) ( 54,017 )
( 59,171 )Foreign exchange loss( 1,033 )
( 756 ) ( 3,577 )
( 5,181 )/'Loss on extinguishment and modification   
( 1,425 )of debt4,Income before income tax provision (benefit)~
~
6R
~
~=~
7Dlsg[OC0~kJ,B !"#$%&'()*+,./' and equity in loss of investees&!Income tax provision (benefit)~
!^!!~
!R.!!! ( 38,631 !)!~
!
*!#"Equity in loss of investees~
"""~
"""~
" +""~
"
B"#
Net income~
#>##~
# ##~
# ~m##~
#
2#$$$$$$ $$
&%Net income per ordinary share:%%%%% %%
&Basic&?&&&(\@&&& @&&&
Q@&'Diluted'{Gz?'''HzG@''' 333333@'''
Q@'(%Weightedaverage ordinary shares used~
(u((~
(((~
( rx((~
(
())!in per share calculations  basic*%Weightedaverage ordinary shares used~
*z**~
***~
* **~
*
*++#in per share calculations  diluted,$____________________________1.)Created by Morningstar Document Research.0/(http://documentresearch.morningstar.com/$*,ec8=PF0*8X>
@c//..******
**
((((((
((
''''''
''
&&&&&&
&&
######
##
""""""
""
!!!!!!
!!
l )
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }6}$ }$}$ }$}
$ }$}$ }$
Jazz Pharmaceuticals plc10Q
11/05/2019A9CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
Net income~
>
~
~
~m
~
2
!Other comprehensive loss:
0(Foreign currency translation adjustments( 48,448 )( 11,984 ) ( 56,271 )
( 43,945 )5Unrealized gain (loss) on hedging activities,
( 558 )~
( 5,380 )~
R0(net of income tax (benefit) provision of2*($80), $107, ($769) and $758, respectively Other comprehensive loss( 49,006 )( 11,238 ) ( 61,651 )
( 38,641 )"Total comprehensive income~
Z@~
zm~
2~
n2$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 eYMA5u"pUyv@t=PF0*8X>
@
l 9]
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }2}}$}$ }
} $ }$}$ }$}$ }$} $ }!!$}"$$ }%%$}&$
9.......... .
...
................... Jazz Pharmaceuticals plc10Q
11/05/2019@8CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY
!
Ordinary Shares
Nonvoting Euro Deferred
"
Capital Redemption Reserve
Additional
Accumulated
Retained Earnings
Total
Paidin
OtherEquity
Capital
Comprehensive
Shares
Amount
Shares
Amount
Income (Loss)$Balance at December 31, 2018~
~
~
>
~
~
b~
z !"#
$( 197,791 %)&~
'jU3)*~
+L2*Cumulative effect adjustment from adoption   

  ~
K~
K!#of new accounting standards2*Issuance of ordinary shares in conjunction~
 

~
/  ~
/!&with exercise of share options2*Issuance of ordinary shares in conjunction~
.  

    !.&with vesting of restricted stock units1)Shares withheld for payment of employee's   

( 13,810 )  ( 13,810 !)!withholding tax liability Sharebased compensation   

~
V  ~
V!Shares repurchased
( 858 )  

   ( 111,249 ) ( 111,249 !) Other comprehensive loss   

 ( 22,883 ) ( 22,883 !)
Net income   

  ~
F3~
F3!!Balance at March 31, 2019~
y~
~
>
~
~
b~
$( 220,674 )~
*
2~
>!2*Issuance of ordinary shares in conjunction~
 

~
m  ~
m!&with exercise of share options2*Issuance of ordinary shares under employee~
 

~
B^  ~
B^!stock purchase planDulfZNB6(dHkH .!.".#.$.%.&.'.(.).*.+.,..../.0.1.2.3.4.5.6.7.8.2 *Issuance of ordinary shares in conjunction~
>  

     !.!&with vesting of restricted stock units1")Shares withheld for payment of employee's """ """ "" "
""
" """"( 1,003 ")" """ """"( 1,003 "!)!#withholding tax liability $Sharebased compensation $$$ $$$ $$ $
$$
$ $$$~
$ʿ$$ $$$ $$$~
$ʿ$!%Shares repurchased
%( 447 %)% %%% %% %
%%
% %%% %%% %%%%( 59,869 %)%%( 59,869 %!)"&Other comprehensive income &&& &&& && &
&&
& &&& &&&~
&&& &&&~
&&!'
Net income ''' ''' '' '
''
' ''' ''' '''~
'*''~
'*'! (Balance at June 30, 2019~
(t((~
(((~
(>( (
~
((
(~
(b((~
(
(((
$( 210,436 ()(~
(^>((~
(*(!2)*Issuance of ordinary shares in conjunction~
))) ))) )) )
))
) )))~
))) ))) )))~
))!&*with exercise of share options2+*Issuance of ordinary shares in conjunction~
+++ +++ ++ +
++
+ +++ +++ +++ +++ ++!.,&with vesting of restricted stock units1)Shares withheld for payment of employee's    

 ( 1,087 )  ( 1,087 !)!.withholding tax liability /Sharebased compensation /// /// // /
//
/ ///~
/F// /// ///~
/F/!0Shares repurchased
0( 149 0)0 000 00 0
00
0 000 000 0000( 19,997 0)00( 19,997 0!) 1Other comprehensive loss 111 111 11 1
11
1 111 1111( 49,006 1)1 1111( 49,006 1!)2
Net income 222 222 22 2
22
2 222 222 222~
2>22~
2>2!%3Balance at September 30, 2019~
3t33~
333~
3>3 3
~
33
3~
3b33~
3ֆ333
$( 259,442 3)3~
3zdC33~
3m3!45$6____________________________17)Created by Morningstar Document Research.08(http://documentresearch.morningstar.com/6 VFi}K;R}qe==PF0*8X>
@88!77!66!33333333333333 22222222222222 11111111111111 00000000000000 //////////////  ++++++++++++++ )))))))))))))) (((((((((((((( '''''''''''''' &&&&&&&&&&&&&& %%%%%%%%%%%%%% $$$$$$$$$$$$$$ """""""""""""" #$'(+,
!
!
l 9
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }2}}$}$ }
} $ }$}$ }$}$ }$} $ }!!$}"$$ }%%$}&$
9.......... .
...
................... Jazz Pharmaceuticals plc10Q
11/05/2019LDCONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (Continued)
!
Ordinary Shares
Nonvoting Euro Deferred
"
Capital Redemption Reserve
Additional
Accumulated
Retained Earnings
Total
Paidin
OtherEquity
Capital
Comprehensive
Shares
Amount
Shares
Amount
Income (Loss)$Balance at December 31, 2017~
~
~
>
~
~
b~
!v !"#
$( 140,878 %)&~
'8)*~
+&2*Cumulative effect adjustment from adoption   

 ~
( 351 )
( 298 !)#of new accounting standards2*Issuance of ordinary shares in conjunction~
 

~
r  ~
r!&with exercise of share options2*Issuance of ordinary shares in conjunction~
 

    !.&with vesting of restricted stock units1)Shares withheld for payment of employee's   

( 14,594 )  ( 14,594 !)!withholding tax liability Sharebased compensation   

~
R{  ~
R{!Shares repurchased
( 237 )  

  ( 34,546 )( 34,546 !)"Other comprehensive income   

 ~
& ~
&!
Net income   

  ~
~
!!Balance at March 31, 2018~
V~
~
>
~
~
b~
^w $( 98,768 )~
j8~
.!2*Issuance of ordinary shares in conjunction~
&  

~
>  ~
>!&with exercise of share options2*Issuance of ordinary shares under employee~
 

~
U  ~
U!stock purchase planD{lZNB6*~vO3{V{B .!.".#.$.%.&.'.(.).*.+.,..../.0.1.2.3.4.5.6.7.8.2 *Issuance of ordinary shares in conjunction~
B  

     !.!&with vesting of restricted stock units1")Shares withheld for payment of employee's """ """ "" "
""
" """"( 1,429 ")" """ """"( 1,429 "!)!#withholding tax liability $Sharebased compensation $$$ $$$ $$ $
$$
$ $$$~
$ښ$$ $$$ $$$~
$ښ$!%Shares repurchased
%( 135 %)% %%% %% %
%%
% %%% %%% %%%%( 21,015 %)%%( 21,015 %!) &Other comprehensive loss &&& &&& && &
&&
& &&& &&&&( 69,460 &)& &&&&( 69,460 &!)'
Net income ''' ''' '' '
''
' ''' ''' '''~
'''~
''! (Balance at June 30, 2018~
(((~
(((~
(>( (
~
((
(~
(b((~
(U(((
$( 168,228 ()(~
(=((~
('(!2)*Issuance of ordinary shares in conjunction~
))) ))) )) )
))
) )))~
) )) ))) )))~
) )!&*with exercise of share options2+*Issuance of ordinary shares in conjunction~
+z++ +++ ++ +
++
+ +++ +++ +++ +++ ++!.,&with vesting of restricted stock units1)Shares withheld for payment of employee's    

 ( 1,169 )  ( 1,169 !)!.withholding tax liability /Sharebased compensation /// /// // /
//
/ ///~
/b// /// ///~
/b/!0Shares repurchased
0( 128 0)0 000 00 0
00
0 000 000 0000( 21,454 0)00( 21,454 0!) 1Other comprehensive loss 111 111 11 1
11
1 111 1111( 11,238 1)1 1111( 11,238 1!)2
Net income 222 222 22 2
22
2 222 222 222~
2 22~
2 2!%3Balance at September 30, 2018~
333~
333~
3>3 3
~
33
3~
3b33~
3B~333
$( 179,466 3)3~
3jD33~
3Ÿ3!45$6____________________________17)Created by Morningstar Document Research.08(http://documentresearch.morningstar.com/6,VF]q?/FqeY1=PF0*8X>
@88!77!66!33333333333333 22222222222222 11111111111111 00000000000000 //////////////  ++++++++++++++ )))))))))))))) (((((((((((((( '''''''''''''' &&&&&&&&&&&&&& %%%%%%%%%%%%%% $$$$$$$$$$$$$$ """""""""""""" #$'(+,
!
!
l M3BG
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }U5}$ }$}$ }$
M
Jazz Pharmaceuticals plc10Q
11/05/20197/CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended
September 30,~
~
Operating activities
Net income~
~m~
2.&Adjustments to reconcile net income to2*net cash provided by operating activities:%Intangible asset amortization~
2~
.u Sharebased compensation~
J*~
Impairment charges ~
BDepreciation~
~
4,Acquired inprocess research and development~
^ "Loss on disposal of assets~
"~
2
Deferred tax benefit ( 167,935 )( 44,658 )3+Provision for losses on accounts receivable~
<~
I
and inventory/'Loss on extinguishment and modification ~
Fof debt2*Amortization of debt discount and deferred~
~
vfinancing costs#Other noncash transactions( 4,437 )~
l*"Changes in assets and liabilities:D
locWK?]m7j
>igT !"#$%&'()*+,./0123456789:;<=>? Accounts receivable ( 4,307 ) ( 55,518 )!Inventories!( 23,028 !)!!( 7,583 !)1")Prepaid expenses and other current assets"( 22,858 ")"~
"6m" #Other noncurrent assets~
#.###
#( 244 #)$Operating lease assets~
$$$ $$%Accounts payable~
%%%~
%%&Accrued liabilities&( 37,369 &)&~
&&'Income taxes payable~
''''( 13,999 ')(Deferred revenue(( 4,234 ()((( 5,623 ()%)Other noncurrent liabilities)( 3,634 )))~
)2q)1*)Operating lease liabilities, less current*( 3,137 *)* **+portion1,)Net cash provided by operating activities~
,n*,,~
,"s#,Investing activities.%Proceeds from maturity of investments~
.2..~
."".(/ Net proceeds from sale of assets ///~
/r/20*Purchases of property, plant and equipment0( 32,998 0)00( 15,221 0)/1'Asset acquisition, net of cash acquired1( 55,074 1)1 1142,Acquired inprocess research and development2( 61,700 2)2 22(3 Acquisition of intangible assets3( 80,500 3)33 ( 111,100 3)"4Acquisition of investments4 ( 585,975 4)44 ( 921,250 4)05(Net cash provided by (used in) investing~
5:555 ( 434,479 5)6
activities7Financing activities777/8'Proceeds from employee equity incentive~
888~
8b!89and purchase plans:%Payment of employee withholding taxes:( 15,900 :)::( 17,192 :)%;related to sharebased awards$<Repayments of longterm debt<( 25,040 <)<<( 17,370 <)=Share repurchases= ( 191,115 =)==( 77,015 =)2>*Proceeds from tenant improvement allowance >>>~
>>?on buildtosuit leaseDl0L)Zq^4EN]wNl@ABCDEFGHIJKL*@"Payment of debt modification costs @@@@( 6,406 @)A%Net cash used in financing activitiesA ( 205,965 A)AA( 32,674 A)1B)Effect of exchange rates on cash and cash
B( 838 B)B
B( 672 B)Cequivalents1D)Net increase in cash and cash equivalents~
DƢDD~
D^D/E'Cash and cash equivalents, at beginning~
EEE~
EΏEF of period3G+Cash and cash equivalents, at end of period~
G0GG~
G*uGHI$J____________________________1K)Created by Morningstar Document Research.0L(http://documentresearch.morningstar.com/
y=PF0*8X>
@]LLKKJJGGGGEEEEDDDDBBBBAAAA@@@@>>>>====<<<<::::8888555544443333222211110000////....,,,,****))))((((''''&&&&%%%%$$$$####""""!!!!
l [
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)Asset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }1}$ }$}$
Jazz Pharmaceuticals plc10Q
11/05/2019,$Adoption of New Accounting Standards
Balance at December 31,
Transition Adjustments
Balance at January 1,~
~
Assets: *
"Property, plant and equipment, net~
:
$( 95,397
)
~
h
Operating lease assets ~
~
Liabilities: Accrued liabilities~
*~
~
r1)Operating lease liabilities, less current ~
Y ~
Y portion%Deferred tax liabilities, net~
~
F~
%Other noncurrent liabilities~
[
( 113,615 )~
lShareholders' Equity: Retained earnings~
jU3~
K~
*3$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<
znbVJ0}ZEQ=PF0*8X>
@
l k
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting Stan!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }$4}$ }$
Jazz Pharmaceuticals plc10Q
11/05/2019Asset Acquisition
Consideration
3+Upfront payment for acquisition of Cavion's~
R4outstanding shares
Cash acquired~
6
"Working capital adjustment
( 255 )Transaction costs~
6,Total consideration~
b/'Assets Acquired and Liabilities AssumedCash~
6+#Inprocess research and development~
NDeferred tax assets~
$Other assets and liabilities( 1,196 )!Total net assets acquired~
b$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/>0ui]f"[1g(=PF0*8X>
@j
l )~
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }a}$
Jazz Pharmaceuticals plc10Q
11/05/20191)3. Cash and AvailableforSale Securities
September 30, 2019 Amortized
Gross
Gross
EstimatedCash andInvestmentsCost
Unrealized
Unrealized
Fair ValueCash
Gains
Losses
EquivalentsCash~
n$
$
$~
n$~
n$
$
Time deposits~
BY  ~
BY ~
b~
Money market funds~
 ~
~
Totals~
~QA
$
$~
~QA~
0~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2I
ui]QE%< , =PF0*8X>
@R*
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }a}$
Jazz Pharmaceuticals plc10Q
11/05/20191)3. Cash and AvailableforSale Securities
December 31, 2018 Amortized
Gross
Gross
EstimatedCash andInvestmentsCost
Unrealized
Unrealized
Fair ValueCash
Gains
Losses
EquivalentsCash~
(
$
$~
(
~
(
$
Time deposits~
n  ~
n ~
nMoney market funds~
 ~
~
Totals~
T2
$
$~
T2~
~
n$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2G
ui]QE%=."=PF0*8X>
@R*
l "+
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }m)}$
"
Jazz Pharmaceuticals plc10Q
11/05/2019!4. Fair Value Measurement
September 30, 2019
December 31, 2018QuotedSignificant
Total
QuotedSignificant
Total Prices in
Other Estimated
Prices in
Other Estimated
Active
Observable
Fair Value
Active
Observable
Fair ValueMarkets forInputs
Markets forInputs Identical (Level 2)
Identical (Level 2)Assets
Assets (Level 1)
(Level 1)Assets:
&Availableforsale securities:
Time deposits
$~
BY ~
BY
$~
n~
nMoney market funds~
~
~
~
Interest rate contracts ~
~
~
?~
?*"Foreign exchange forward contracts ~
~
~
~
Totals~
~
i ~
iSXTj^ !1 )Created by Morningstar Document Research.0!(http://documentresearch.morningstar.com/=PF0*8X>
@S!!
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }6}$ }$}$ }$}
$ }$}$
Jazz Pharmaceuticals plc10Q
11/05/2019805. Derivative Instruments and Hedging Activities
Three Months Ended
Nine Months Ended
September 30,
September 30, Interest Rate Contracts:~
~
~
~

%Gain (loss) recognized in accumulated
$( 322
)
~
$( 4,361
)
~
R
,$other comprehensive loss, net of tax1)Loss (gain) reclassified from accumulated
( 236 )
( 130 ) ( 1,019 )~
N5other comprehensive loss to interest expense,
net of tax$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.nbVJ>~+ah`J"=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }0}$
Jazz Pharmaceuticals plc10Q
11/05/2019805. Derivative Instruments and Hedging Activities
Three Months Ended
Nine Months Ended
September 30,
September 30,+#Foreign Exchange Forward Contracts:~
~
~
~
0
(Loss recognized in foreign exchange loss~
t
~
%
~
z
~
B
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*hnbVJ>~+V~V=PF0*8X>
@z
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }7}$}$ }y#}$
Jazz Pharmaceuticals plc10Q
11/05/2019805. Derivative Instruments and Hedging Activities
September 30, 2019Asset DerivativesLiability DerivativesBalance Sheet Location
Fair ValueBalance Sheet Location
Fair Value6
.Derivatives designated as hedging instruments:
Interest rate contractsOther current assets~
Accrued liabilities~
%Other noncurrent liabilities~
%Derivatives not designated as hedging instruments:*"Foreign exchange forward contractsOther current assets~
Accrued liabilities~
22*Total fair value of derivative instruments~
~
:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6nbVJ>.F6Ys=PF0*8X>
@z
l n
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }7}}$ }$}$
Jazz Pharmaceuticals plc10Q
11/05/2019805. Derivative Instruments and Hedging Activities
December 31, 2018Asset DerivativesLiability DerivativesBalance Sheet Location
Fair ValueBalance Sheet Location
Fair Value6
.Derivatives designated as hedging instruments:
Interest rate contractsOther current assets~
&Accrued liabilities
$ Other noncurrent assets~
v! %Derivatives not designated as hedging instruments:*"Foreign exchange forward contractsOther current assets~
Accrued liabilities~
2*Total fair value of derivative instruments~
BR~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6nbVJ>/G<$_y=PF0*8X>
@z
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }$}$ }$}
$ }$}$ }$}$ }$
Jazz Pharmaceuticals plc10Q
11/05/2019805. Derivative Instruments and Hedging Activities
September 30, 20197/Gross Amounts of Recognized Assets/ Liabilities0(Gross Amounts Offset in the Consolidated4 ,Net Amounts of Assets/ Liabilities Presented4
,Gross Amounts Not Offset in the Consolidated
Balance Sheet) !in the Consolidated Balance Sheet
Balance Sheet
Description
(
Derivative Financial Instruments
*
"Cash Collateral Received (Pledged)
Net AmountDerivative assets~
$~
$( 772 )
$~
Derivative liabilities( 3,758 )  ( 3,758 )~
( 2,986 )$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.N nbVJ>2 =PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }$}$ }$}
$ }$}$ }$}$ }$
Jazz Pharmaceuticals plc10Q
11/05/2019805. Derivative Instruments and Hedging Activities
December 31, 20187/Gross Amounts of Recognized Assets/ Liabilities0(Gross Amounts Offset in the Consolidated4 ,Net Amounts of Assets/ Liabilities Presented4
,Gross Amounts Not Offset in the Consolidated
Balance Sheet) !in the Consolidated Balance Sheet
Balance Sheet
Description
(
Derivative Financial Instruments
*
"Cash Collateral Received (Pledged)
Net AmountDerivative assets~
BR
$~
BR
$( 935 )
$~
CDerivative liabilities( 1,460 )  ( 1,460 )~

( 525 )$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.K nbVJ>3
=PF0*8X>
@
l #
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }0}$
Jazz Pharmaceuticals plc10Q
11/05/20196. Inventories
September 30,
December 31,~
~
Raw materials~
~
>
Work in process~
>
~
D
Finished goods~
~
MTotal inventories~
W~
r;$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.5xl`*u=PF0*8X>
@z
l /
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }y#}$ }$
Jazz Pharmaceuticals plc10Q
11/05/2019)!7. Goodwill and Intangible Assets $
Balance at December 31, 2018~
:8
Foreign exchange( 20,905 )%Balance at September 30, 2019~
W7
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(T}qeYM[OC=PF0*8X>
@2
l 'H
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }+} } $ }
$}$ }$}$
Jazz Pharmaceuticals plc10Q
11/05/2019)!7. Goodwill and Intangible Assets
September 30, 2019
December 31, 2018 Remaining
GrossAccumulatedNet Book
GrossAccumulatedNet Book WeightedCarryingAmortization
ValueCarryingAmortization
Value
Average Useful
Amount
AmountLife
(In years)'Acquired developed technologies+@~
v
$( 790,075
)~
>~
۽
$( 632,413 )~
RBPriority review voucher~

~
~
~
Manufacturing contracts ~
"( 11,656
) ~
( 12,256 ) 
Trademarks ~
( 2,881
) ~
B( 2,896 ) ,$Total finitelived intangible assets~
" ( 804,612
)~
~
z ( 647,565 )~
F
Acquired IPR&D assets~
> 
~
>~
֪ ~
֪Total intangible assets~
*`
$( 804,612
)~
D~
N;
$( 647,565 )~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<}qeYM 0vY)=PF0*8X>
@B
l KW
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }}$
Jazz Pharmaceuticals plc10Q
11/05/2019)!7. Goodwill and Intangible Assets
Year Ending December 31,
EstimatedAmortizationExpense
2019 (remainder)~
.
~
~
~
~
J~
~
f ~
~
f
Thereafter~
\
Total~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6}qeYMkCpdX0=PF0*8X>
@j
l h
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }7}$ }$}$ }$
Jazz Pharmaceuticals plc10Q
11/05/2019&8. Certain Balance Sheet Items
September 30,
December 31,~
~
Leasehold improvements~
:~
Land and buildings~
n
~
Computer software~
ƽ~
)%Manufacturing equipment and machinery~
~
Computer equipment~
~
Furniture and fixtures~
^~
n Constructioninprogress~
f[~
Buildtosuit facility ~
Subtotal~
~
A6.Less accumulated depreciation and amortization( 52,855 )( 49,608 )*"Property, plant and equipment, net~
~
:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<th\PsV%`
=PF0*8X>
@
l {
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }7}$
Jazz Pharmaceuticals plc10Q
11/05/2019&8. Certain Balance Sheet Items
September 30,
December 31,~
~
*"Rebates and other sales deductions~
B~
~G*
"Employee compensation and benefits~
N
~
6.Current portion of operating lease liabilities~
"Inventoryrelated accruals~
~
ƈClinical trial accruals~
~
B\&Selling and marketing accruals~
h~
i Royalties~
^~
)Professional fees~
A~
v$( Accrued constructioninprogress~
/~
Sales returns reserve~
,~
:'Accrued interest~
'~
s)!Derivative instrument liabilities~
%~
Accrued loss contingency ~
Other~
~
Rd!Total accrued liabilities~
R~
*$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/D
lth\PsU9l@~rJ=PF0*8X>
@*%
l Q
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }0.}$ }$}$ }$
Jazz Pharmaceuticals plc10Q
11/05/20199. Debt
September 30,
December 31,~
~
2021 Notes~
b#~
b#.
&Unamortized discount and debt issuance
( 44,566
)
( 60,910
)costs on 2021 Notes2021 Notes, net~
` ~
`
2024 Notes~
b#~
b#.&Unamortized discount and debt issuance ( 123,310 ) ( 138,914 )costs on 2024 Notes2024 Notes, net~
~
ڝ Term loan~
r%~
rq'
Total debt~
"a~
oaLess current portion~
~
Total longterm debt~
v_~
Ff_$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/BXsg4:
23}=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }}$
Jazz Pharmaceuticals plc10Q
11/05/2019
Maturities
Year Ending December 31,+
#Scheduled LongTerm Debt Maturities2019 (remainder)~
n~
~
~
~
"%
~
~
~
~
ڕ
Thereafter~
b#
Total~
fl$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2pd4[3p=PF0*8X>
@Z
l U
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }}$ }$}$ }$
Jazz Pharmaceuticals plc10Q
11/05/2019
10. Leases
Lease Cost
Three Months Ended
Nine Months EndedSeptember 30, 2019September 30, 2019Operating lease cost~
Y~
"
Shortterm lease cost~
2
~
B
Variable lease cost ~
Sublease income
( 158 )
( 478 )Net lease cost~
]~
%$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0pdS4wk_7=PF0*8X>
@
l c
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }<(}1}$
Jazz Pharmaceuticals plc10Q
11/05/2019
10. Leases
Leases
Classification
September 30,~
Assets
Operating lease assets
Operating lease assets~
ڨ
LiabilitiesCurrent% Operating lease liabilitiesAccrued liabilities~
Noncurrent% Operating lease liabilities1)Operating lease liabilities, less current~
j] portion)!Total operating lease liabilities~
n
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:pd(5U&<0$=PF0*8X>
@J
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }2} }$
Jazz Pharmaceuticals plc10Q
11/05/2019
10. Leases $
Lease Term and Discount Rate
September 30,~
%Weightedaverage remaining lease term~
*"
 operating leases (years)2*Weightedaverage discount rate  operating333333@ %leases$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/, pd@t
=PF0*8X>
@*
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }I;}$
Jazz Pharmaceuticals plc10Q
11/05/2019
10. Leases
Nine Months EndedSeptember 30, 201991Cash paid for amounts included in the measurement
of lease liabilities:.&Operating cash outflows from operating~
leases&Noncash operating activities:0(Rightofuse assets obtained in exchange~
bW /'for new operating lease liabilities (1)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2pd4w+bV.=PF0*8X>
@:
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }m)}$ }$
Jazz Pharmaceuticals plc10Q
11/05/2019
10. Leases
Year Ending December 31,
Operating leases2019 (remainder)~
F~
~
jG~
~
E
~
~
fF~
~
2L
Thereafter~
Total lease payments~
;
Less imputed interest( 51,624 )*"Present value of lease liabilities~
n
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6spd4nFr*=PF0*8X>
@j
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }I;}$ }$}$ }$}
$ }$
Jazz Pharmaceuticals plc10Q
11/05/2019,$Accumulated Other Comprehensive Loss
Net Unrealized
Foreign
Total Gain (Loss) From HedgingCurrency Accumulated
ActivitiesTranslation
Other
Adjustments
Comprehensive Loss$Balance at December 31, 2018~
7
$( 201,348 )
$( 197,791 )91Other comprehensive loss before reclassifications( 4,361 )( 56,271 ) ( 60,632 )%Amounts reclassified from accumulated( 1,019 )  ( 1,019 ) other comprehensive loss%Other comprehensive loss, net( 5,380 )( 56,271 ) ( 61,651 )%Balance at September 30, 2019$( 1,823 )
$( 257,619 )
$( 259,442 )$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 znbVJX8r'=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }U5}$
Jazz Pharmaceuticals plc10Q
11/05/2019)!13. Net Income per Ordinary Share
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
Numerator:
Net income~
>~
~
~m~
2Denominator:
%Weightedaverage ordinary shares used~
u~
~
rx~
)!in per share calculations  basic4,Dilutive effect of employee equity incentive~
~
~
N~
Fand purchase plans%Weightedaverage ordinary shares used~
z~
~
~
+#in per share calculations  diluted
&Net income per ordinary share:
Basic?(\@ @
Q@Diluted{Gz?HzG@ 333333@
Q@$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/BX}qeYM:S&bDXz=PF0*8X>
@#
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }}
}$ }
}$ }
} $ }
}$
Jazz Pharmaceuticals plc10Q
11/05/2019)!13. Net Income per Ordinary Share
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
!
Exchangeable Senior Notes~
V
~
V
~
V
~
V
Options, RSUs and ESPP~
O~
#~
rO ~
~.$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,}qeYMj YMA=PF0*8X>
@Z
l *
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }%}$
Jazz Pharmaceuticals plc10Q
11/05/201914. Revenues
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
Xyrem~
~
~
I
~
R>
Erwinaze/Erwinase~
~
~
z~
*/ Defitelio/defibrotide~
K~
F5~
~
Vyxeos~
6~
H~
z~
FSunosi~
n ~
n

Other~
F~
~
6~
Product sales, net~
} ~
d~
(_~
nU'Royalties and contract revenues~
T~
BA~
JG~
Total revenues~
~
~
o`~
UV$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:
znbOWp)r=PF0*8X>
@z/
l :
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }}$
Jazz Pharmaceuticals plc10Q
11/05/201914. Revenues
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
United States~
:
~
:
~
W
~
^N
Europe~
v#~
~
2~
V All other~
~
~
@~
VTotal revenues~
~
~
o`~
UV$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0NznbOZ=PF0*8X>
@
l I
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }}$}$}$ }$}$}$ }$}$} $ }
$}$
Jazz Pharmaceuticals plc10Q
11/05/201914. Revenues
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
Express Scripts~
>
%
~
2
%
~
2
%
~
&
%McKesson~
2 %~
> %~
: % ~
J %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,znb5"~rf>=PF0*8X>
@Z
l rV
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }0.}$ }$
Jazz Pharmaceuticals plc10Q
11/05/2019/'Contract Liabilities  Deferred Revenue
Contract Liabilities'Balance as of December 31, 2018~
N.&Amount recognized within royalties and( 4,234 )
contract revenues( Balance as of September 30, 2019~
&$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,Hwk_SGT7=PF0*8X>
@:
l h
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }:}$ }$}$ }$}
$ }$}$ }$
Jazz Pharmaceuticals plc10Q
11/05/2019$15. ShareBased Compensation
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
+
#Selling, general and administrative~
:=
~
(
~
~
z
Research and development~
e~
G~
~
Cost of product sales~
~
~
S~
zN/'Total sharebased compensation expense,~
~
>~
J*~
pretax80Income tax benefit from sharebased compensation( 4,106 )( 3,552 ) ( 12,246 )
( 12,066 )expense/'Total sharebased compensation expense,~
~
P~
j~
net of tax$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 vj^R?"u=PF0*8X>
@#
l w
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased CompensationRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }6}$ }$}$ }$}
$ }$}$ }$
Jazz Pharmaceuticals plc10Q
11/05/2019
Share Options
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~

%Shares underlying options granted (in~
~
~
~
thousands)Grant date fair value(\OD@ףp=
J@ )\(E@
yG@5BlackScholes option pricing model assumption
information:
Volatility~
%~
%~
%~
%Expected term (years)@@ @
@ Range of riskfree rates1.51.7%2.72.8% 1.52.5%
2.22.8%Expected dividend yield  %  %  %
 %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:8
ymaNg
@#
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }!}$
Jazz Pharmaceuticals plc10Q
11/05/2019Restricted Stock Units
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~
#
RSUs granted (in thousands)~
B
~
~
~
Grant date fair value`@(\e@ Pa@
{G2b@$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,pdXE#=PF0*8X>
@
l ҙ
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }a/}'
Jazz Pharmaceuticals plc10Q
11/05/2019Sleep/Neuroscience
Product Candidates
Description)!Submitted for Regulatory Approval+#Sunosi in the European Union, or EU( EDS in OSA and EDS in narcolepsy
Phase 3
/'JZP258 (oxybate; 92% sodium reduction)'Cataplexy and EDS in narcolepsy/'JZP258 (oxybate; 92% sodium reduction)Idiopathic hypersomniaPhase 2bJZP385 (CX8998)( Essential tremor (planned study)Preclinical( Oxybate oncenightly formulation
Narcolepsy$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6th\D{\@=PF0*8X>
@
l J
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }2}8
J
Jazz Pharmaceuticals plc10Q
11/05/2019Hematology/Oncology
Product Candidates
DescriptionPhase 3 Defitelio/'Prevention of VOD in highrisk patients
following HSCTVyxeos2*AML or highrisk myelodysplastic syndrome,4,or MDS (AML19 and AML 18) (cooperative groupstudy)Vyxeos%Newly diagnosed adults with standard3+and highrisk AML (cooperative group study)Vyxeos3+Newly diagnosed pediatric patients (planned%Children?s Oncology Group cooperativegroup study) Phase 2/32*JZP458 (recombinant Erwinia asparaginase)ALL/LBLPhase 2 Defitelio5Prevention of acute Graft versus Host Disease!following allogeneic HSCT Defitelio3+Prevention of CAR Tcell therapyassociated
neurotoxicityVyxeos + venetoclax/'De novo or relapsed/refractory, or R/R,7/AML (MD Anderson Cancer Center, or MD Anderson,collaboration study)Dlsg[C9Q=S. !"#$%&'()*+,./0123456789:;<=>? Vyxeos/ 'Highrisk MDS (European Myelodysplastic!/!'Syndromes Cooperative Group cooperative""group study)#Vyxeos6#.R/R AML (Children?s Oncology Group cooperative$$group study)%Vyxeos3%+Newly diagnosed older adults with highrisk&&%AML (planned cooperative group study)'Vyxeos + venetoclax0'(Highrisk AML (planned cooperative group((study))Phase 1)*Vyxeos + gemtuzumab0*(R/R AML or hypomethylating agent failure++%MDS (MD Anderson collaboration study),Vyxeos + venetoclax,%Low intensity therapy for firstline,"unfit AML (Phase 1b study)(. Vyxeos + various targeted agents4.,Firstline, fit AML (planned Phase 1b study)/Vyxeos0/(Low intensity dosing for higher risk MDS0)0!(MD Anderson collaboration study)1IMGN632/1'CD123+ hematological malignancies (Jazz202(optin opportunity with ImmunoGen, Inc.)*3"IMGN632 +/ venetoclax/azacitidine03(CD123+ AML (Jazz optin opportunity with4*4"ImmunoGen, Inc.; Phase 1b/2 study)5Preclinical56 CombiPlex6Solid tumors candidate7 CombiPlex27*Hematology/oncology exploratory activities28*JZP341 (longacting Erwinia asparaginase)08(ALL and other hematological malignancies949,(collaboration with Pfenex, Inc., or Pfenex) :Recombinant pegaspargase/:'Hematological malignancies (Jazz optin; ;opportunity with Pfenex)< Defitelio<Exploratory activities=Exosome NRAS candidate1=)Hematological malignancies (collaboration>1>)with Codiak Biosciences, Inc., or Codiak)?Exosome STAT3 candidate1?)Hematological malignancies (collaborationD
lXbB\WahS@ABCDEFGHI@@with Codiak) AExosomebased candidates/A'Solid tumors/hematological malignanciesB#B(collaboration with Codiak)!CPanRAF inhibitor program0C(RAF and RAS mutant tumors (acquired fromD.D&Redx, which is continuing development)EF$G____________________________1H)Created by Morningstar Document Research.0I(http://documentresearch.morningstar.com/R{=PF0*8X>
@IIHHGG
l !
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncology
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }6}$ } $}
$}$ }$}$
!
Jazz Pharmaceuticals plc10Q
11/05/2019Results of Operations
Three Months Ended
Increase/
Nine Months Ended
Increase/
September 30,
September 30,~
~
(Decrease)~
~
(Decrease)
Product sales, net~
}
~
d
~
:
%
~
(_
~
nU
~
.
%'Royalties and contract revenues~
T~
BA~
v
%~
JG~
~
%5Cost of product sales (excluding amortization~
~
:~
J
%~
~
~
%of intangible assets)+#Selling, general and administrative~
J
~
~
>
%~
~
 % Research and development~
~
b~
%~
Y~
_
~
N %%Intangible asset amortization~
>~
6~
%~
2~
.u ~
F %Impairment charges   N/A(1)
~
BN/A(1)4,Acquired inprocess research and development~
(  N/A(1)
~
^ N/A(1)Interest expense, net~
~
'~
%~
L~
~
%Foreign exchange loss~
&~
~
%~
7~
P~
%/'Loss on extinguishment and modification   N/A(1)
~
FN/A(1)of debt&Income tax provision (benefit)~
^~
R. N/A(1)
~
f~
*N/A(1)#Equity in loss of investees~
~
~
"
%~
+~
B~
%$____________________________1)Created by Morningstar Document Research.Dl}qeYQNqikhmW\aQ>43' 0 (http://documentresearch.morningstar.com/H=PF0*8X>
@C
l i
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }%}$ } $}
$}$ }$}$
Jazz Pharmaceuticals plc10Q
11/05/2019Revenues
Three Months Ended
Increase/
Nine Months Ended
Increase/
September 30,
September 30,~
~
(Decrease)~
~
(Decrease)
Xyrem~
~
~
N
%
~
I
~
R>
~
F
%Erwinaze/Erwinase~
~
~
%~
z~
*/ ~
%Defitelio/defibrotide~
K~
F5~
%~
~
~
2 %Vyxeos~
6~
H~
%~
z~
F~
R %Sunosi~
n  N/A(1)
~
n N/A(1)
Other~
F~
~
.
%~
6~
~
%Product sales, net~
} ~
d~
:
%~
(_~
nU~
. %'Royalties and contract revenues~
T~
BA~
v
%~
JG~
~
%Total revenues~
~
~
>
%~
o`~
UV~
2 %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:~rf^[=PF0*8X>
@3
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }}$
Jazz Pharmaceuticals plc10Q
11/05/2019)!Research and Development Expenses
Three Months Ended
Nine Months Ended
September 30,
September 30,~
~
~
~

%Clinical studies and outside services~
f
~
~
~
M
Personnel expenses~
~~
~
~
5Milestone expense~
~
~
Other~
~
^r~
~
j0
Total~
~
b~
Y~
_
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/26}qeYM:!y?3'=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }1}$
Jazz Pharmaceuticals plc10Q
11/05/2019jbTo continue to grow our business, we will need to commit substantial resources, which could result
Nine Months Ended
September 30,~
~
1
)Net cash provided by operating activities~
n*
~
"s#
0(Net cash provided by (used in) investing~
:~
F{
activities%Net cash used in financing activities~
m~
z1)Effect of exchange rates on cash and cash~
~
equivalents1)Net increase in cash and cash equivalents~
Ƣ~
^$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6<0$^*A+E.y=PF0*8X>
@
l P
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our businesprovided however!A general release does not exte!A general release does not (1)!A general release does not (2)U }'}}$ }}
$
Jazz Pharmaceuticals plc10Q
11/05/2019%Issuer Purchases of Equity Securities
,
$Total Number of Shares Purchased (1)
(
Average Price Paid per Share (2)
0
(Total Number of Shares Purchased as Part

%Maximum Number (or Approximate Dollar/'of Publicly Announced Plans or Programs
2*Value) of Shares that May Yet Be Purchased~
'Under the Plans or Programs (4)
July 1  July 31, 2019~
\(Da@
~
~
B0
"August 1  August 31, 2019~
CGz`@~
C
~
f'V.
( September 1  September 30, 2019~
z(\`@~
z
~
,
Total~
: Gz`@~
:
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0ymaUI6sg?=PF0*8X>
@
l .
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secu!A general release does not exte!A general release does not (1)!A general release does not (2)U }:}$ }$}$
Jazz Pharmaceuticals plc10Q
11/05/2019provided, however 8
0If the Participant is at the time of the Covered
Applicable Percentage:
Termination a:Vice President~
%
%Senior Vice President, Executive Vice
~
Z
%4,President, or above (but not Chief Executive1)Officer, Executive Chairman or President)3+Chief Executive Officer, Executive Chairman~
" %or President$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/04ui]\9!=PF0*8X>
@
l .:
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not (1)!A general release does not (2)U }$
Jazz Pharmaceuticals plc10Q
11/05/2019kcA general release does not extend to claims which the creditor does not know or suspect to exist in
EXECUTIVE
Name:
Date:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.;/#aI =PF0*8X>
@2
l TF
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (2)U }$
Jazz Pharmaceuticals plc10Q
11/05/2019kcA general release does not extend to claims which the creditor does not know or suspect to exist in
EXECUTIVE
Name:
Date:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.;/#aI =PF0*8X>
@2
l zR
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??5!JAZZ PHARMACEUTICALS PUBLIC LIM!Waterloo Road Dublin 4 Ireland
SIGNATURES!CONDENSED CONSOLIDATED BALANCE !CONDENSED CONSOLIDATED STATEMEN!CONDENSED CONSOLIDATED STAT (1)!CONDENSED CONSOLIDATED STAT (2)!CONDENSED CONSOLIDATED STAT (3)!CONDENSED CONSOLIDATED STAT (4)!Adoption of New Accounting StanAsset Acquisition!3 Cash and AvailableforSale Sec!3 Cash and AvailableforSale (1)4 Fair Value Measurement!5 Derivative Instruments and He!5 Derivative Instruments an (1)!5 Derivative Instruments an (2)!5 Derivative Instruments an (3)!5 Derivative Instruments an (4)!5 Derivative Instruments an (5)
6 Inventories!7 Goodwill and Intangible Asset!7 Goodwill and Intangible A (1)!7 Goodwill and Intangible A (2)8 Certain Balance Sheet Items8 Certain Balance Sheet I (1)9 Debt
Maturities 10 Leases
10 Leases (1)
10 Leases (2)
10 Leases (3)
10 Leases (4)!Accumulated Other Comprehensive!13 Net Income per Ordinary Shar!13 Net Income per Ordinary (1)
14 Revenues14 Revenues (1)14 Revenues (2)!Contract Liabilities Deferred R15 ShareBased Compensation
Share OptionsRestricted Stock UnitsSleepNeuroscienceHematologyOncologyResults of Operations
Revenues!Research and Development Expens!To continue to grow our busines!Issuer Purchases of Equity Secuprovided however!A general release does not exte!A general release does not (1)U }$
Jazz Pharmaceuticals plc10Q
11/05/2019kcA general release does not extend to claims which the creditor does not know or suspect to exist in
EXECUTIVE
Name:
Date:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.;/#aI =PF0*8X>
@2
Root Entry FBook
S
!"#$%&'()*+,./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{}~
!"#$%&'()*+,./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{}~
!"#$%&'()